Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 8/20 | 0.42 |
| ▸ | QPCT | Q16769 | 6/20 | 0.42 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7663787 | 0.90 | PDE4B (0.42) | PDE4BPDE4DGSK3BQPCTHTR6 | |
| SCHEMBL8362797 | 0.90 | PDE4B (0.43) | PDE4BPDE4DGSK3BQPCTCAMK2D | |
| SCHEMBL7658242 | 0.90 | MAOB (0.38) | PDE4BPDE4DCAMK2DKDR | |
| SCHEMBL7664768 | 0.89 | CAMK2D (0.46) | GSK3BCAMK2DCNR2KDR | |
| SCHEMBL7662560 | 0.89 | PDE4B (0.40) | PDE4BPDE4DGSK3BQPCTHTR6 | |
| SCHEMBL7662842 | 0.89 | PDE4B (0.40) | PDE4BPDE4DGSK3BQPCTPRKD1 | |
| SCHEMBL7659720 | 0.87 | CAMK2D (0.36) | PDE4BPDE4DGSK3BQPCTTDP1 | |
| SCHEMBL7657341 | 0.86 | CAMK2D (0.36) | PDE4BPDE4DGSK3BQPCTCAMK2D | |
| SCHEMBL7659626 | 0.86 | CAMK2D (0.43) | GSK3BCAMK2DKDR | |
| SCHEMBL8516344 | 0.85 | CAMK2D (0.40) | PDE4BPDE4DGSK3BQPCTCAMK2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458792-B1 | MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. | ASTRAZENECA AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1071683-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999046264-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 1999-09-16 | — | — | WO | disclosed |